Imagenebio (IMA)Director bought ~$96K

~$96K

Approx. value · 16K sh @ $5.99

16K

Holds after · shares reported

Traded

Dec 24, 2025

Filed

Dec 29, 2025

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

1. Oct 23, 2025Company filing · Form 8-K · Material agreement, Agreement endedSigned an important agreement, and ended an important agreement
2. Nov 1, 2025Company filing · Form 8-K · Executive changeChanged a top executive or board member“On November 1, 2025, the Board of Directors (the “Board”) of ImageneBio, Inc. (the “Company”) increased the authorized size of the Board from six directors to seven directors and, upon recommendation of the Nominating and Corporate Governance Committee of the Board, appointed Joseph P. Slattery to the Board, effective November 1, 2025, and as the Chair of the Audit Committee of the Board, effective November 18, 2025.”
3. Nov 12, 2025Company filing · Form 8-K · ResultsReported its results
4. Dec 12, 2025Company filing · Form 8-K · Executive changeChanged a top executive or board member“On December 12, 2025, Yufang Lu, M.D., Ph.D., our Chief Medical Officer, provided notice of her resignation, effective December 31, 2025. Dr. Lu’s resignation was not due to any disagreement on any matter relating to our operations, policies or practices.”
5. Dec 24, 2025 · this disclosureInsider · Their first buy on recordDirector purchased ~$96K of IMA shares in the open market

What came next

1. Feb 12, 2026Company filing · Form 8-K · Executive changeChanged a top executive or board member“On February 12, 2026, Steven Hui Wang resigned as a member of the Board of Directors (the “Board”) of ImageneBio, Inc. (the “Company”), effective immediately. Mr. Wang’s resignation was not the result of any disagreement with the Company on any matter related to the Company’s operations, policies, practices or strategy.”
2. Mar 10, 2026Company filing · Form 8-K · ResultsReported its results
3. Mar 12, 2026Company filing · Form 8-K · Executive changeChanged a top executive or board member“On March 12, 2026, ImageneBio, Inc. (the “Company”) and Erin Butler, the Company’s Senior Vice President, Finance & Administration and Principal Accounting Officer, agreed to a mutual separation effective March 20, 2026 (the “Butler Separation Date”).”
4. Apr 12, 2026Company filing · Form 8-K · Material agreement, Unregistered sharesSigned an important agreement, and sold new shares without registering them

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for Imagenebio

For Imagenebio, OQRO holds 2 insider filings (SEC Form 4 or Form 144) and 1 fund holdings report (13F) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its IMA page.

How this filing works

• SEC Form 4
• Open-market purchase
• Rule 10b5-1 trading plans

Other disclosures at Imagenebio

• SEC Form 13F-HRAug 14, 2026
• SEC Form 4Jul 21, 2026
• SEC Form 4Jul 21, 2026
• SEC Form 13F-HRMay 15, 2026
• SEC Form 4Jul 30, 2025
• SEC Form 4Jul 30, 2025

Everything OQRO holds on this company is on its IMA page.